ENCell Co (XKRX:456070) Debt-to-Asset : 0.10 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is ENCell Co Debt-to-Asset?

ENCell Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩1,320 Mil. ENCell Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩3,097 Mil. ENCell Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₩43,981 Mil. ENCell Co's debt to asset for the quarter that ended in Dec. 2023 was 0.10.

ENCell Co Debt-to-Asset Historical Data

The historical data trend for ENCell Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENCell Co Debt-to-Asset Chart

ENCell Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.35

0.10

0.09

0.10

ENCell Co Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Debt-to-Asset	0.35	0.10	0.09	0.10

Competitive Comparison of ENCell Co's Debt-to-Asset

For the Biotechnology subindustry, ENCell Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ENCell Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ENCell Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ENCell Co's Debt-to-Asset falls into.

ENCell Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ENCell Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1319.749	+	3097.371)	/	43981.151
	=	0.10

ENCell Co's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1319.749	+	3097.371)	/	43981.151
	=	0.10

ENCell Co (XKRX:456070) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ENCell Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ENCell Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ENCell Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Yeongdong-daero, 11th floor, Gangnam-gu, Seoul, KOR

Website

http://www.encellinc.com

ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.

ENCell Co Headlines

No Headlines